Cantor Fitzgerald Initiates Coverage on Sunesis Pharmaceuticals with Buy Rating, $6 PT

In a report released earlier today, Cantor Fitzgerald L.P. announced that it is initiating coverage on Sunesis Pharmaceuticals, Inc.

with a Buy rating and a price target of $6. Cantor Fitzgerald said in the report “We like Sunesis for its opportunity to launch vosaroxin into an area of substantial medical need (AML) and believe that a recent deal with Royalty Pharma is a major de-risking event for the company.” Sunesis Pharmaceuticals, Inc. closed at $2.63 yesterday.